NCT05265234: Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
- State
- State not given
- Phase
- Phase 4
- People
- 15 planned
- Started
- 1 Mar 2022
- Primary completion
- 1 Mar 2023
- Arms
- Dupixent
- Results
- None posted
- 3 Mar 2022: Trial registered
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.